Researchers at the University of British Columbia Okanagan have published a mathematical argument that, they say, rules out ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.53, demonstrating a +2.02% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of ...

Ask the publishers to restore access to 500,000+ books. An icon used to represent a menu that can be toggled by interacting with this icon. A line drawing of the Internet Archive headquarters building ...

In “The Great Math War,” Jason Socrates Bardi takes on a battle for the soul of numbers that divided the experts of its day. By Jordan Ellenberg Jordan Ellenberg, a professor of mathematics at the ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Abstract: Since many mathematical morphology operations are recursive transforms of dilation and erosion, this paper proposes fast recursive transforms to reduce computational complexity. The basic ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly. Recursion ...

Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development. It remains to ...